A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: treatment planning and quality assurance by unknown
Otani et al. Radiation Oncology  (2015) 10:126 
DOI 10.1186/s13014-015-0430-8RESEARCH Open AccessA Japanese prospective multi-institutional
feasibility study on accelerated partial
breast irradiation using interstitial
brachytherapy: treatment planning and
quality assurance
Yuki Otani1*, Takayuki Nose2, Takushi Dokiya3, Toshiaki Saeki4, Yu Kumazaki5, Shuuji Asahi6, Iwao Tsukiyama7,
Ichirou Fukuda8, Hiroshi Sekine9, Naoto Shikama5, Takao Takahashi4, Ken Yoshida10, Tadayuki Kotsuma11,
Norikazu Masuda12, Eisaku Yoden13, Kazutaka Nakashima14, Taisei Matsumura15, Shino Nakagawa16, Seiji Tachiiri17,
Yoshio Moriguchi18, Jun Itami19 and Masahiko Oguchi20Abstract
Background: In Japan, breast-conserving surgery with closed cavity has generally been performed for breast cancer
patients, and accelerated partial breast irradiation (APBI) is considered difficult because Asian females generally have
smaller breast sizes than Western females. Therefore, common identification of target and treatment plan method
in APBI is required. A prospective multicenter study was conducted in Japan to determine institutional compliance
with APBI using high-dose-rate interstitial brachytherapy (ISBT) designed for Japanese female patients.
Methods: For this study, 46 patients were recruited at eight institutions from January 2009 to December 2011. The
reproducibility of the ISBT–APBI plan was evaluated using three criteria: (1) minimum clinical target volume dose with a
clip dose≥ 6 Gy/fraction, (2) irradiated volume constraint of 40-150 cm3, and (3) uniformity of dose distribution,
expressed as the dose non-uniformity ratio (DNR, V150/V100) < 0.35. The ISBT–APBI plan for each patient was
considered reproducible when all three criteria were met. When the number of non-reproducible patients was ≤
4 at study completion, APBI at this institution was considered statistically reproducible.
Results: Half of the patients (52 %) had a small bra size (A/B cup). The mean values of the dose-constrained parameters
were as follows: Vref, 117 cm3 (range, 40-282), DNR, 0.30 (range, 0.22-0.51), and clip dose, 784 cGy (range, 469-3146). A
total of 43/46 treatment plans were judged to be compliant and ISBT–APBI was concluded to be reproducible.
Conclusions: This study showed that multi-institutional ISBT–APBI treatment plan was reproducible for small breast
patient with closed cavity.
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In Japan, the incidence and mortality rate of breast can-
cer is growing rapidly, and the annual number of cases
is expected to rise above 50,000 by 2020 [1]. Further-
more, the peak age for breast cancer in Japan is 10 years
younger than that in Europe and USA, and the disease
rate in 45–50-year-old females is high [2].
Breast-conserving surgery followed by postoperative
radiotherapy is the standard of care for early-stage breast
carcinoma [3, 4]. Generally, postoperative irradiation by
whole-breast irradiation (WBI) reduces the rate of ipsilat-
eral breast recurrence by one-third [4, 5]. However, stud-
ies have also reported that WBI prevents recurrence only
near the tumor bed [3, 4, 6]. Moreover, WBI raises the
mortality rate by increasing the risk of cardiovascular ad-
verse events [5]. Thus, localized irradiation of the tumor
bed is preferable for patients at a low risk of recurrence.
Accelerated partial breast irradiation brachytherapy
(APBI) delivers radiation near the tumor bed over a
short period of time [7–11]. In Europe and the USA,
successful phase I/II clinical trials were completed in the
1990s, and large-scale phase III clinical trials are cur-
rently underway [8, 10]. In contrast, APBI is rarely used
in Japan. One reason for this is the difficulty in target
identification, caused by oncoplastic surgery, which is
generally adopted in Japan. Moreover, APBI is consid-
ered difficult because Asian females generally have
smaller breast sizes than Western females.
To promote APBI using interstitial brachytherapy, de-
veloping target identification consensus and reproduci-
bility of this treatment among institutions should be first
confirmed prospectively. This study presents the creative
method of clinical target volume (CTV) and dose limita-
tion for Asian females. Then, the reproducibility of inter-
stitial brachytherapy (ISBT)-APBI is evaluated in breast




A multi-institutional clinical trial was conducted from
October 2009 to December 2011 at eight institutions in
Japan. In total, 46 female patients with breast cancer
were recruited prospectively for this study to receive ad-
juvant radiotherapy by ISBT–APBI alone after breast-
conserving surgery.
The Institutional Review Board (IRB) of each institu-
tion approved this study. Written informed consent for
data acquisition was obtained from each patient.
Surgery
All patients underwent breast-conserving surgery, de-
fined as resection of the primary tumor with > 0 cm of
microscopic free margin. During surgery, the walls ofthe excision cavity were marked with at least four clips
on the superior, inferior, medial, and lateral margins of
the tumor bed. The brachytherapy applicators were
inserted within 2 months after the breast-conserving
surgery. All needles were inserted under image guidance
by computed tomography (CT) or ultrasonography (US).
More two-plane implants were made. The needles were
replaced with flexible catheters and fixed with buttons.
If applicator placement was judged insufficient during
treatment planning, additional insertions were made.
Brachytherapy
After applicator implantation, CT data were acquired with
the patient in a supine position. CT slice thickness was <
3.0 mm. CT-based treatment planning was performed
with the aid of Oncentra or PLATO (Nucletron BV, Vee-
nendaal, The Netherlands). The high-dose-rate (HDR)-
ISBT protocol was performed with microSelectron-HDR
V2 using 192Ir as the source for monotherapy.
The clinical target volume was defined by drawing 3-
cm diameter circles around each clip, and was consid-
ered to be the domain to which they were clinically con-
nected (Fig. 1). The breast muscle layer and tissue of up
to 5 mm depth from the skin surface were excluded. In
addition, non-mammary gland tissue domain falling
under CTV, identified by a consensus of the radiation
oncologist and the breast surgeon, was excluded from
CTV. The initial dose distribution was made using the
Paris dosimetry system, which was modified by manual
geometrical optimization when the skin dose was re-
duced. The brachytherapy was initiated the next day
after applicator placement. A total dose of 36 Gy (six
fractions of 6 Gy) was delivered as two fractions per day
with an interval of 6 h between the two fractions.
Dose specification
Compliance of each institution to the APBI protocol was
assessed using three criteria:
1. Clip dose: The surgical clips in CTV were irradiated
by >100 % of the isodose lines. A clip outside a
mammary gland was excluded as an object. No
exception was permitted.
2. Reference volume (Vref ): The irradiated volume
receiving >100 % of the prescription dose was 40-
150 cm3. An exception was made for specific condi-
tions (e.g., larger breast) under the approval of the
study office and data center.
3. Dose non-uniformity ratio (DNR): The ratio was de-
fined as the irradiated volume that received ≥ 1.5
times the reference dose over the volume that re-
ceived ≥ 1.0 times the reference dose (DNR =
V1.5ref/Vref ). For all patients, DNR must be < 0.35,
with no exception.
Fig. 1 Clinical target volume (CTV) defines method
Otani et al. Radiation Oncology  (2015) 10:126 Page 3 of 7Compliance with the treatment plan was acknowledged
when all three criteria were within the reference range.
Quality assurance
To improve the quality of this study, workshops, rapid
review, and Interim analysis were established. Quality
assurance was implemented according to Radiation Therapy
Oncology Group (RTOG) procedures [12]. Moreover, the
data center predicted the total irradiation time from the Vref
and source activity.
Workshops
Three workshops were conducted to homogenize treat-
ments between institutions. A radiation oncologist, a breast
surgeon, a medical physicist, and a radiation technologist
from each institution participated in all three workshops.
The participants discussed the process of applicator inser-
tion and the treatment plan. Moreover, each institution was
instructed to submit their calculation of the benchmark
treatment plan using uniform sample patient data, and the
submitted data were verified at the data center.Table 1 Patient demographics
Variable Mean ± SD (Range) N (%)
Weight (kg) 60 ± 11 (43 – 96)
Height (cm) 155 ± 6 (140 – 170)
Body Mass Index 25.0 ± 4.8 (18.4 – 41.6)
Number of catheters (n) 15 ± 3 (8 – 21)
Breast excision weight (g) 82 ± 44 (25 – 234)
Volume of CTV (cm3) 67 ± 29 (26 – 133)
Bra size
A cup 10 (22)
B cup 14 (30)
C cup 11 (24)
≥ D cup 11 (24)Rapid review
Each institution was required to fax a case report form
(CRF) to the data center at least 24 h before the onset of
treatment. The treatment plan summary contained no
patient identifier. If there was any doubt, the data center
queried the relevant institution and consulted with the
study office. The data center and study office verified the
following parameters: applicator length, offset value, clip
dose, Vref, DNR, maximum skin dose, total treatment
time, and source strength.
Interim and final analyses
The number of patients required for the statistical ana-
lysis was determined on the basis of the optimal design
of Simon [13]. Interim analysis was performed with data
from 19 patients, and this clinical trial was planned to
be stopped when non-compliance with the plan was
confirmed for >3 patients. Final analysis was performed
with data from 46 patients. The ISBT–APBI plan was
defined as reproducible if non-compliance with the plan
was confirmed for < 5 patients. The electronic data onTable 2 Index parameters of the treatment plan
Variable Mean ± SD (Range)
Vref (cm3) 117 ± 56 (40 – 282)
DNR 0.30 ± 0.05 (0.22 – 0.51)
Clip dose (cGy) 784 ± 224 (469 – 3146)
Max skin dose (cGy) 521 ± 73 (223 – 607)
CTV V1.5ref (cm3) 39 ± 18 (12 – 98)
CTV V2.0ref (cm3) 15 ± 9 (5 – 58)
CTV V100 (cm3) 63 ± 27 (25 –129)
CTV V90 (cm3) 63 ± 28 (26 – 131)
CTV D100 (cGy) 565 ± 125 (146 – 624)
CTV D90 (cGy) 680 ± 97 (225 – 731)
CTV Mean dose (cGy) 927 ± 80 (760 – 1092)
Conformity Index 2.07 ± 0.84 (1.07 – 4.45)
Fig. 2 Frequency distribution of the index parameters of the ISBT–APBI treatment plan. a Reference volume (Vref). b Dose non-uniformity ratio
(DNR). c Clip dose. d Percent CTV coverage
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to Oncentra at the data center anonymously. The data
center and study office reviewed all treatment plans.
Results
Patient demographics and treatment plan index
The patient demographics are shown in Table 1. The pa-
tients were subjected to postoperative implantation by
closed cavity (after breast-conserving surgery, n = 45) orFig. 3 The relationship among activity, time and Vref. Activity is the activity
Vref is the reference volumeperioperative implantation (during intra-breast-conserving
surgery, n = 1). There were 24 patients (52 %) with a small
bra size (A or B cup). Table 2 shows the index parameters
of the treatment plan. The mean values of the dose-
constrained parameters were as follows: Vref, 117 cm3
(range, 40-282), DNR, 0.30 (range, 0.22-0.51), and clip dose,
784 cGy (range, 469-3146). Fig. 2 shows the normal fre-
quency distributions for Vref, DNR, clip dose, and percent
CTV coverage among patients. The relationship amongthe high-dose-rate source, time (s) is the total irradiation time, and
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Fig. 3. The correlation factors for in small bra size and large
bra size patients were 0.821 and 0.928, respectively.
Validation of the reference volume
The data center and study office evaluated the adequacy of
the Vref values that were outside the 40-150 cm3 range. In
total, 14 patients had a Vref above the upper limit, with a
median of 191 cm3 (range, 169-287). The patients with a
Vref of > 150 cm3 had a median body mass index (BMI) of
28.3 (range, 25.5-41.6) and a median excision weight of
110 g (range, 60-234). In contrast, those with a Vref of ≤
150 cm3 had a median BMI of 22.5 (range, 18.4-30.8) and a
median excision weight of 61 g (range, 25-100). All exceed-
ing Vref values were determined to be appropriate.
Interim and final analyses
The interim analysis identified two non-compliant treat-
ment plans. The analysis report was submitted to the safetyFig. 4 The relationship between irradiated volume, fat necrosis, and local conmonitoring committee, and clinical trial continuation was
approved. In the final analysis, one more treatment plan
was judged non-compliant with the protocol.
In case #1, the DNR value was 0.51, which was not
within the acceptable limit (<0.35). This discrepancy was
due to the large size of the patient’s breast (I cup). The
target was larger than expected because the cavity was
filled with fluid, which required several applicators.
However, the patient refused the insertion of additional
applicators. In case #2, the CTV creative method was
not in accordance with the protocol. Not all 3-cm
spheres created around the clips were connected. How-
ever, the dose distribution was connected, which was
judged to be clinically satisfactory. In case #3, the one
clip dose was 469 cGy, less than the reference value
and wrong clip dose value was written in CRF. Thus,
a total of 43/46 treatment plans were judged to be
compliant and ISBT–APBI was concluded to be
reproducible.trol rate. a fat necrosis and Vref. b relationship local control rate and Vref
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This study was designed to evaluate the reproducibility
of ISBT–APBI for breast cancer patients among Japa-
nese institutions. To our knowledge, this is the first re-
ported ISBT–APBI multi-institutional clinical trial in
Asia. In this study, ISBT–APBI was compliant for 43/46
patients. Although ISBT involves multiple manual proce-
dures, standardization of the treatment plan is possible
through comprehensive webinars. Two cases (case #2
and #3) deviated from the protocol due to a human
error detected in CRF. Thus, careful review of the elec-
tronic data on the treatment plan is essential to secure
the quality of a multicenter clinical trial.
Based on preceding literature, two indices (Vref and
DNR) of a brachytherapy plan are found to be important
for local control and sequel. Figure 4 shows the relation-
ship between irradiated volume, fat necrosis, and local
control rate which have been reported by some authors
[11, 14–21]. Wazer et al. reported that Vref, V1.5xref,
and V2.0ref correlated with fat necrosis [16, 22]. Ott
et al. concluded that irradiation volume correlated sig-
nificantly with side-effects and local control, and a suit-
able upper limit of Vref was 150-180 cm3 for a closed
cavity [9]. In contrast, Perera et al. reported a local con-
trol ratio of 84 % in an irradiated volume of 30 cm3 [17].
In literature from Germany and Austria, the Vref range
was 48-84 cm3 [9, 18–20]. The protocol of the Phase III
multi-institutional clinical trial of the Groupe Européen
de Curiethérapie-European Society for Therapeutic Radi-
ology and Oncology (GEC-ESTRO) adopted a Vref range
of 40-150 cm3 with a DNR of < 0.35 [10]. In USA, the rate
of open cavity breast surgery and the radiation volume are
larger than those in Europe and Japan. Thus, the reference
indicators of The National Surgical Adjuvant Breast and
Bowel Project (NSABP)/RTOG 0413 [8, 10] may not apply
to other continents.
Most patients with excessive Vref had a pyknic body
type and required large-weight excisions. Moreover, six
(13 %) patients had a BMI of > 30, corresponding to a
3.2 % deviation (Organization for Economic Co-operation
and Development Health data 2009 [23]) from the general
Japanese female population. There is a possibility that the
APBI plan deliberately selected large-breast patients, be-
cause most Japanese females have small breasts and inser-
tion of the applicator is difficult. This ISBT–APBI plan
provided a better coverage of the target area, because a
median 98 % of CTV received 100 % of the prescription
dose, compared to 96 % of the single-institutional study
by Das et al. [24].
The quality assurance methods of HDR treatment
planning have been reported [24–26]. One of a quick,
easy way of checking is a method to infer the total ir-
radiation time from the source activity and the Vref. Ac-
cording to our results, there is low correlation amongthe Vref, the source activity and the total treatment time
in the small bra-size treatment plan compared with that
in the large bra-size treatment plan (Fig. 3). For small
bra size patients, applicator insertion is difficult and the
applicator spacing tends to be irregular and narrow.
Moreover, each point source stop time in the small
bra-size patient treatment plan is short compared with
that in the large bra-size patient. The Vref increases
exponentially with increasing source stop time because
the dose distribution expands concentrically. There-
fore, the method of inferring total irradiation time
from the source activity and Vref is difficult to adjust
to patients with small breasts.
Conclusions
This prospective study defined an ISBT–APBI treatment
plan to be clinically feasible for most Asian females with
a closed cavity and small breast size. Furthermore, the
treatment plan was reproducible between institutions,
despite various levels of skills and experience with the
technique.
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